Equity Overview
Price & Market Data
Price: $2.27
Daily Change: +$0.01 / 0.44%
Range: $2.25 - $2.46
Market Cap: $61,453,668
Volume: 133,530
Performance Metrics
1 Week: -3.81%
1 Month: -14.34%
3 Months: -49.78%
6 Months: -84.27%
1 Year: -82.48%
YTD: -46.34%
Company Details
Employees: 76
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.